Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients

被引：0

作者：

Angell, Helen ^{[1
]}

Ros, Vidalba Rocher ^{[1
]}

Standifer, Nathan ^{[2
]}

Lai, Zhongwu ^{[1
]}

Gresty, Christopher ^{[1
]}

Delord, Jean-Pierre ^{[3
]}

De Jonge, Maja ^{[4
]}

Postel-Vinay, Sophie ^{[5
]}

Italiano, Antoine ^{[6
]}

Krebs, Matthew G. ^{[7
,8
]}

Kaufman, Bella ^{[9
]}

Park, Yeon Hee ^{[10
]}

Domchek, Susan ^{[11
]}

Herbolsheimer, Pia ^{[12
]}

Hodgson, Darren ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

[2] MedImmune, Mountain View, CA USA

[3] Inst Claudius Regaud Oncopole, Toulouse, France

[4] Erasmus MC Canc Inst, Rotterdam, Netherlands

[5] Gustave Roussy Canc Campus, Villejuif, France

[6] Inst Bergonie, Bordeaux, France

[7] Univ Manchester, Manchester, Lancs, England

[8] Christie NHS Fdn Trust, Manchester, Lancs, England

[9] Sheba Med Ctr, Ramat Gan, Israel

[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[11] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[12] AstraZeneca, Gaithersburg, MD USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P257

引用

页数：2